Recipient selection

Chest Surgery Clinics of North America

Volumn 13, Issue 3, 2003, Pages 405-428

  Yu, Andrew D ^a   Garrity, Edward R ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DATA BASE; DIAGNOSTIC ACCURACY; EISENMENGER COMPLEX; HUMAN; LUNG FIBROSIS; LUNG INSUFFICIENCY; LUNG TRANSPLANTATION; LUNG VOLUME; MORTALITY; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECIPIENT SELECTION; REVIEW; RISK FACTOR; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0042861767     PISSN: 10523359     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3359(03)00057-7     Document Type: Review

References (101)

1. International Society of Heart and Lung Transplantation (ISHLT) Registry 2002 statistics. Available at: http://www.ishlt.org. Accessed December 11, 2002.
2. De Meester J, Smits JM, Persijn GG, Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease: the Eurotransplant experience. J Heart Lung Transplant 2001;20:518-24.
3. Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. Transplantation 1998;66(7):951-6.
4. Smith CM. Patient selection, evaluation and preoperative management for lung transplant candidates. Clin Chest Med 1997;18(2):183-97.
5. Patterson GA. Indications: unilateral, bilateral, heart-lung and lobar transplant procedures. Clin Chest Med 1997;18(2):225-30.
6. Travers GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. Am Rev Respir Dis 1979;119:895-902.
7. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:961-6.
8. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434-40.
9. Marquis K, Debigare R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:809-13.
10. Meyers BF, Yusen RD, Guthrie TJ, Davis G, Phol MS, Lefrak SS, et al. Outcome of bilateral lung volume reduction in patients with emphysema potentially eligible for lung transplantation. J Thorac Cardiovasc Surg 2001;122(1):10-6.
11. Geddes D, Davies M, Koyama H, Hansell D, Pastorino U, Pepper J, et al. Effect of lung volume reduction surgery in patients with severe emphysema. N Engl J Med 2000;343(4):239-45.
12. National Emphysema Treatment Trail Research Group. Patients at high risk of death after lung volume reduction surgery. N Engl J Med 2001;345(15):1075-83.
13. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998;351:24-7.
14. Kerem E, Reisman J, Corey M, Canny GJ, Levinson H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326(18):1187-91.
15. Sharples L, Hathaway T, Dennis C, Caine N, Higenbottam T, Wallwork J. Prognosis of patients with cystic fibrosis awaiting heart and lung transplantation. J Heart Lung Transplant 1993;12: 669-74.
16. Augarten A, Akons H, Aviram M, Bentur L, Blau H, Picard E, et al. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant 2001;5: 339-42.
17. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998;113:1230-4.
18. Liou TG, Adler FR, Cahill BC, FitzSimmons SC, Huang D, Hibbs JR, et al. Priorities for lung transplantation among patients with cystic fibrosis [letter to the editor]. JAMA 2002; 287(12):1523.
19. 1 as a guide to lung transplant referral in young patients with cystic fibrosis. Pediatr Pulmonol 2000;30:198-202.
20. Moorcroft AJ, Dodd ME, Webb AK. Exercise testing and prognosis in adult cystic fibrosis. Thorax 1997;52:291-3.
21. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJS, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001;56:746-50.
22. Vizza CD, Yusen RD, Lynch JP, Fedele F, Patterson GA, Trulock EP. Outcome of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2000;162:819-25.
23. Tantisira KG, Systrom DM, Ginns LC. An elevated breathing reserve index at the lactate threshold is a predictor of mortality in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2002;165:1629-33.
24. Stanchina ML, Tantisira KG, Aquino SL, Wain JC, Ginns LC. Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. J Heart Lung Transplant 2002;21:217-25.
25. Snell GI, Bennetts K, Bartolo J, Levvey B, Griffiths A, Williams T, et al. Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation. J Heart Lung Transplant 1998;17:1097-103.
26. McCloskey M, McCaughan J, Redmond AOB, Elbom JS. Clinical outcome after acquisition of Burholderia cepacia in patients with cystic fibrosis. Ir J Med Sci 2001;170(1):28-31.
27. Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ. Outcome of Burhkholderia cepacia colonisation in an adult cystic fibrosis center. Thorax 2002;57:142-5.
28. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138:699-704.
29. Hayllar KM, Williams SG, Wise AE, Pouria S, Lombard M, Hodson ME, et al. A prognostic model for the prediction of survival in cystic fibrosis. Thorax 1997;52:313-7.
30. Liou TG, Adler FR, Cahill BC, FitzSimmons SC, Huang D, Hibbs JR, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 2001;286(21):2683-9.
31. Schwartz DA, Helmers RA, Galvin JR, VanFossen DS, Frees KL, Dayton CS, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994;149: 450-4.
32. King TE, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA, et al. Idiopathic pulmonary fibrosi: relationship between histopathological features and mortality. Am J Respir Crit Care Med 2001;164:1025-32.
33. Nicholson AG, Fulford LG, Colby TV, duBois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:173-7.
34. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995;108:305-10.
35. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Resp Crt Care Med 2000;162:1109-14.
36. 99mTc-DTPA aerosol clearance and survival in usual interstitial pneumonia. Thorax 2001; 56:916-23.
37. Timmer SJ, Karamzadeh AM, Yung GL, Kriett J, Jamieson SW, Smith CM. Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia. Chest 2002;122: 779-84.
38. King TE, Tooze JA, Schwartz MI, Brown KR, Chemiack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164: 1174-81.
39. Mogulkoc N, Brutshce MH, Bishop PW, Greaves M, Horrocks AW, Egan JJ. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung trasplantation. Am J Respir Crit Care Med 2001;164:103-8.
40. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L. A preliminary study of long term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9.
41. D'Alonzo GE, Barst RI, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Ann Intem Med 1991;115:343-9.
42. Ewert R, Wensel R, Opitz C, Habedank D, Lodziewski S, Hummel M, et al. Prognosis in patients with primary pulmonary hypertension awaiting lung transplantation. Transplant Proc 2001;33:3574-5.
43. Nootens M, Freels S, Kaufmann E, Levy PS, Rich S. Timing of single lung transplantation for primary pulmonary hypertension. J Heart Lung Transplant 1994;13:276-81.
44. Lopes AA, Maeda NY. Circulating von Willebrand factor antigen as a predictor for short term prognosis in pulmonary hypertension. Chest 1998;114:1276-82.
45. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, et al. Serum uric acid levels correlate with the severity and mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999;160:487-92.
46. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, et al. Assessment of survival in patient with primary pulmonary hypertension, importance of cardiopulmonary exercise testing. Circulation 2002;106:319-24.
47. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski H, Schultheiss H, et al. Big endothelin-I and endothelin-I plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120:1562-9.
48. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension, comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161: 487-92.
49. Bossone E, Paciocco G, Iarussi D, Agretto A, Iacono A, Gillespie BW, et al. The prognostic role of ECG in primary pulmonary hypertension. Chest 2002;121:513-8.
50. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
51. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9.
52. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80:151-5.
53. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long term intravenous epoprostenol infusion in primary pulmonary hypertension. J Am Coll Cardiol 2002;40:780-8.
54. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903.
55. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995;91: 2028-35.
56. Rothman A, Sklansky MS, Lucas VW, Kashani IA, Shaughnessy RD, Channick RN, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999;84:682-6.
57. Hayden A. Balloon atrial septostomy increases cardiac index and may reduce mortality among pulmonary hypertension patients awaiting lung transplantation. J Transpl Coord 1997;7:131-3.
58. Hopkins WE, Ochoa LL, Richardson GW, Trulock FP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996;15:100-5.
59. Waddell TK, Bennett L, Kennedy R, Todd TR, Keshavjee SH. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002;21:731-7.
60. Alvarez A, Lama R, Algar J, Santos F, Briceno J, Aranda JL, et al. Predicting mortality after lung transplantation. Transplant Proc 2001;33(1-2):1630-1.
61. Meyer DM, Bennett LE, Novick RJ, Hosenpud JD. Single vs bilateral, sequential lung transplantation for end stage emphysema: influence of recipient age on survival and secondary end points. J Heart Lung Transplant 2001;20:935-41.
62. Shane E, Silverberg S, Donovan D, Papadopoulos A, Staron RB, Addesso V, et al. Osteoporosis in lung transplantation candidates with end stage pulmonary disease. Am J Med 1996;101: 262-9.
63. Ferrari S, Rizzoli R, Nicod L. Osteoporosis in patients undergoing lung transplantation [letter to the editor]. Chest 1997;111(1):257-8.
64. Aris RA, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest 1996;109:1176-83.
65. Ferrari SL, Nicod LP, Hamacher J, Spiliopoulos A, Slosman DO, Rochat T, et al. Osteoporosis in patients undergoing lung transplantation. Eur Respir J 1996;9:2378-82.
66. Aringer M, Kiener HP, Koeller MD, Artemiou O, Zuckermann A, Wieselthaler G, et al. High turnover bone disease following lung transplantation. Bone 1998;23:485-8.
67. Shane E, Papadopoulos A, Staron RB, Addesso V, Donovan D, McGregor C. et al. Bone loss and fracture after lung transplantation. Transplantation 1999;68(2):220-7.
68. Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation, a prospective study. Chest 2000;117:476-81.
69. Ott SM, Aitken ML. Osteoporosis in patients with cystic fibrosis. Clin Chest Med 1998;19(3): 555-67.
70. Henderson K, Eisman J, Keogh A, MacDonald P, Glanville A, Spratt P, et al. Protective effect of short term calcitrol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res 2001;16:565-71.
71. Cahill BC, O'Rourke MK, Parker S, Stringham JC, Karwande SK, Knecht TP. Prevention of bone loss and fracture after lung transplantation. Transplantation 2001;72(7):1251-5.
72. Aris RM, Lester GE, Renner JB, Winders A, Blackwood AD, Lark RK, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 2000;162:941-6.
73. Lima O, Cooper JD, Peters WJ, Ayabe H, Townsend E, Luk SC, et al. Effects of methylprednisolone and azathioprine on bronchial healing after lung transplantation. J Thorac Cardiovasc Surg 1981;82:211-5.
74. Patterson GA, Cooper JD. Status of lung transplantation. Surg Clin North Am 1988;68: 545-58.
75. Schafers HJ, Wagner TO, Demertzis S, Hamm M, Wahlers T, Cremer J, et al. Preoperative corticosteroids, a contraindication to lung transplantation. Chest 1992;102:1522-5.
76. Kanasky WF, Anton SD, Rodrigue JR, Perri MG, Szwed T, Baz MA. Impact of body weight on long term survival after lung transplantation. Chest 2002;121:401-6.
77. Levine SM, Sako EY. Waiting to make the weight for lung transplantation. Chest 2002;121(2): 317-8.
78. Madill J, Gutierrez C, Grossman J, Allard J, Chan C, Hutcheon M, et al. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant 2001;20:288-96.
79. Schwebel C, Pin I, Branoud D, Devouassoux G, Brichon PY, Chaffanjon PH, et al. Prevalence and consequences of nutritional depletion in lung transplant candidates. Eur Respir J 2000;16: 1050-5.
80. Baz MA, Palmer SM, Staples ED, Greer DG, Tapson VF, Davis D. Lung transplantation after long-term mechanical ventilation. Chest 2001;119:224-7.
81. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of pan resistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997;155:1699-704.
82. Kanj SS, Tapson V, Davis D, Madden J, Browning I. Infections in patients with cystic fibrosis following lung transplantation. Chest 1997;112:924-30.
83. Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993;103(2):466-71.
84. Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T, et al. Infection with Burkhoderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001;163:43-8.
85. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Am J Respir Crit Care Med 2001;164:2102-6.
86. De Soyza A, McDowell A, Archer L, Dark JH, Elbom SJ, Mahenthiralingam E, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001;358:1780-1.
87. LiPuma JJ. Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis. Transplant Infect Dis 2001;3:149-60.
88. Ruffini E, Baldi S, Rapellino M, Cavallo A, Parola A, Robbiano F, et al. Fungal infections in lung transplantation. Incidence, risk factors and prognostic significance. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:181-90.
89. Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterial tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995;152:374-6.
90. Freeman AM, Westphal JR, Davis LL. The future of organ transplant psychiatry. Psychosomatics 1995;36:429-37.
91. Manzetti JD, Ankeny R, Miller D. Pyschosocial and ethical issues in surgical approaches to end-stage lung disease. Clin Chest Med 1997;18(2):383-90.
92. Kotz MM, Stowe JA. Addiction relapse prevention in solid organ transplantation. Transplant Proc 1999;31(Suppl 4A):48S-9S.
93. Zaltzman JS, Pei Y, Maurer J, Patterson A, Cattran DC. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 1992;54(5):875-8.
94. Navis G, Broekroelofs J, Mannes GP, Van Der Bij W, De Boer WJ, Tegzess AM, et al. Renal hemodynamics after lung transplantation. Transplantation 1996;61:1600-5.
95. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993;12:S328-36.
96. Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996;10:248-55.
97. Wigle DA, Chaparro C, Humar A, Hutcheon MA, Chan CK, Keshavjee S. Epsteinn-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001;72(11):1783-6.
98. Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of presentation of early and late cases. J Heart Lung Transplant 2001;20:1054-63.
99. Maurer JR. Evaluation and management of prospective lung and heart-lung recipients. In: Norman DJ, Turka LA, editors. Primer on transplantation. 2nd edition. Mt Laurel (NJ): American Society of Transplantation; 2001. p. 635-44.
100. Kuo PC, Stock PG. Transplantation in the HIV+ patient. Am J Transplant 2001;1(1):13-7.
101. Hosenpud JD, Pamidi SR, Fiol BS, Cinquegrani MP, Keck BM. Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: an analysis and study using the joint ISHLT/UNOS thoracic registry. J Heart Lung Transplant 2000;19:781-5.